NCT03129646 - Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa | Biotech Hunter

Enrollment

439

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Visceral Leishmaniasis

Interventions

DRUG

Miltefosine

Miltefosine 10mg and 50mg capsules

DRUG

Paromomycin

Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp

DRUG

Sodium stibogluconate

Sodium stibogluconate 33% 30 ml inj.

Trial Locations (7)

Kacheliba Hospital, Kapenguria

Abdurafi MSF Health Center, Ābderafī

University Hospital of Gondar, Gonder

El Hassan Centre for Tropical Medicine, Doka

Tabarak Allah MSF Hospital, Gedaref

Um El Kher Hospital, Gedaref

Amudat Hospital, Amudat